[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

P selectin inhibitors - Pipeline Insight, 2021

March 2021 | 60 pages | ID: PB7AD44F1864EN
DelveInsight

US$ 1,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 hours

DelveInsight’s, “P selectin inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in P selectin inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
P selectin inhibitors Understanding

P selectin inhibitors: Overview

P-Selectin (CD62P), previously termed PADGEM or GMP-140, is a single chain glycoprotein of 140 kDa expressed in platelets and endothelial cells. In platelets, P-selectin is stored in ? granules, whereas in endothelial cells it is found in Weibel–Palade bodies. P-selectin mediates the rolling of blood cells on the surface of the endothelium and initiates the attachment of leukocytes circulating in the blood to platelets, endothelial cells, and other leukocytes at sites of tissue injury and inflammation. P-selectin plays a key role in diseases associated with injury and arterial thrombosis. Increased expression of P-selectin is observed in coronary artery disease, acute myocardial infarction, stroke, and peripheral artery diseases. Increased level of sP-selectin and elevated P-selectin expression may be good markers of some types of carcinoma, such as neoplastic pulmonary diseases, breast, renal, and colon cancer, and blood cancer. P-selectin inhibition with protein therapeutics such as antibodies or soluble ligands given intravenously can decrease thrombosis in a mouse ligation model of venous thrombosis. Inhibition of P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) play a key role in proliferation of Multiple myeloma.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence P selectin inhibitors R&D. The therapies under development are focused on novel approaches for P selectin inhibitors.
P selectin inhibitors Emerging Drugs Chapters

This segment of the P selectin inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

P selectin inhibitors Emerging Drugs
  • DSTAT: Chimerix
DSTAT (dociparstat sodium) is an intravenous formulation of chemically modified heparin with very low anticoagulant activity. DSTAT targets key protein pathways important for AML blast cell migration to the bone marrow and retention of these cells in the marrow where they are protected from chemotherapy. DSTAT (CX-01) also binds with proteins involved in chemotherapy resistance and the delay in platelet recovery after chemotherapy. DSTAT is in Phase III clinical trial studies for the treatment of AML. DSTAT has received Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration for the treatment of AML. In July 2019, Chimerix announced the completion of an exclusive worldwide license of DSTAT from Cantex Pharmaceuticals.
  • Inclacumab: Global Blood Therapeutics
Inclacumab is a novel, fully human monoclonal antibody designed to inhibit P-selectin. It is in development for SCD patients with frequent pain crises, also known as vaso-occlusive crises (VOCs). P-selectin inhibition is clinically validated to reduce VOCs, a complication of SCD. We have an exclusive worldwide licensing agreement with Roche for inclacumab. In July 2018, Global Blood Therapeutics received exclusive worldwide rights, and sublicensing rights, to develop, manufacture, and commercialize Roche’s Inclacumab.

Further product details are provided in the report…….

P selectin inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different P selectin inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on P selectin inhibitors
There are approx. 8+ key companies which are developing the P selectin inhibitors. The companies which have their P selectin inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Chimerix.
  • Phases
DelveInsight’s report covers around 8+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
P selectin inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

P selectin inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses P selectin inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging P selectin inhibitors drugs.

P selectin inhibitors Report Insights
  • P selectin inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
P selectin inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing P selectin inhibitors drugs?
  • How many P selectin inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for P selectin inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the P selectin inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for P selectin inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Chimerix
  • Novartis
  • GlycoMimetics
  • Modus Therapeutics
  • Global Blood Therapeutics
  • Suzhou Ronnsi Pharma
Key Products
  • DSTAT
  • Crizanlizumab
  • Rivipansel
  • Sevuparin
  • Inclacumab
  • Depolymerised holothurian glycosaminoglycan
Introduction
Executive Summary
P selectin inhibitors: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
P selectin inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  P selectin inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
P selectin inhibitors Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
DSTAT: Chimerix
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Crizanlizumab: Novartis
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
Inclacumab: Global Blood Therapeutics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
Depolymerised holothurian glycosaminoglycan: Suzhou Ronnsi Pharma
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
P selectin inhibitors Key Companies
P selectin inhibitors Key Products
P selectin inhibitors- Unmet Needs
P selectin inhibitors- Market Drivers and Barriers
P selectin inhibitors- Future Perspectives and Conclusion
P selectin inhibitors Analyst Views
P selectin inhibitors Key Companies
Appendix

LIST OF TABLES

Table 1 Total Products for P selectin inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


LIST OF FIGURES

Figure 1 Total Products for P selectin inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


More Publications